CARA Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

Open

VWAP

Vol

Mkt Cap

16.65M

Low

Amount

EV/EBITDA(TTM)

Total Shares

-13.57M

EV/OCF(TTM)

P/S(TTM)

3.40

Cara Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery, development, and commercialization of novel therapeutics to treat serious medical conditions, including pruritus. The Company’s KORSUVA (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis (HD). Its novel compound, difelikefalin, is a highly selective, primarily peripherally acting kappa opioid receptor (KOR) agonist. The Company is developing an oral formulation of difelikefalin and has Phase III programs ongoing for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease (NDD-CKD), and atopic dermatitis (AD). In addition, the Company has initiated a Phase II/III program of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica (NP).

Events Timeline

(ET)

2025-04-14

11:53:10

Cara Therapeutics board approves 1-for-3 reverse stock split

2024-12-27 (ET)

2024-12-27

06:01:23

Cara Therapeutics announces effective date of 1-for-12 reverse stock split

2024-12-18 (ET)

2024-12-18

06:06:07

Cara Therapeutics, Tvardi Therapeutics enter definitive merger agreement

News

8.5

2025-04-15Business Insider

Cara Therapeutics trading halted, news pending

3.0

2025-03-02SeekingAlpha

Earnings week ahead: TGT, COST, CRWD, AVGO, JD, PLUG, MRVL, and more

7.0

2025-02-21PRnewswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BLUE, VOXX, CARA, CYTH on Behalf of Shareholders

7.0

2025-02-20Businesswire

CARA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cara Therapeutics, Inc. - CARA

7.0

2025-01-07PRnewswire

SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates ML, PWOD, NURO, CARA on Behalf of Shareholders

7.0

2025-01-07Businesswire

CARA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cara Therapeutics, Inc. - CARA

Valuation Metrics

The current forward P/E ratio for Cara Therapeutics Inc (CARA.O) is -1.25, compared to its 5-year average forward P/E of -4.97. For a more detailed relative valuation and DCF analysis to assess Cara Therapeutics Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.97

Current PE

-1.25

Overvalued PE

-0.46

Undervalued PE

-9.48

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.63

Current EV/EBITDA

-0.46

Overvalued EV/EBITDA

0.42

Undervalued EV/EBITDA

-7.68

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

8.61

Current PS

6.51

Overvalued PS

15.30

Undervalued PS

1.92

Financials

AI Analysis

Annual

Quarterly

Whales Holding CARA

Trading Trends

People Also Watch

Frequently Asked Questions

What is Cara Therapeutics Inc (CARA) stock price today?

The current price of CARA is 0 USD — it has increased 0

What is Cara Therapeutics Inc (CARA)'s business?

What is the price predicton of CARA Stock?

Wall Street analysts forecast CARA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CARA is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Cara Therapeutics Inc (CARA)'s revenue for the last quarter?

Cara Therapeutics Inc revenue for the last quarter amounts to 1.46M USD, decreased -51.56

What is Cara Therapeutics Inc (CARA)'s earnings per share (EPS) for the last quarter?

Cara Therapeutics Inc. EPS for the last quarter amounts to -1.68 USD, decreased -76.40

How many employees does Cara Therapeutics Inc (CARA). have?

Cara Therapeutics Inc (CARA) has 55 emplpoyees as of March 26 2026.

What is Cara Therapeutics Inc (CARA) market cap?

Today CARA has the market capitalization of 16.65M USD.

CARA Overview